Viewing nowCombinationOlostat Tablet 20/20 mg (Olmesartan Medoxomil, Rosuvastatin)
Rosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.

MFDS item code 201400426 · Approved 2014.01.29 · Insurance code 641605700
Treatment of essential hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular risk
This medication is intended for patients who require combined administration of the two components, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil is primarily effective for treating essential hypertension. Meanwhile, rosuvastatin is used as an adjunctive treatment for dyslipidemia conditions such as hypercholesterolemia, which cannot be managed by diet and exercise alone. It also helps lower total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It reduces patients’ risk of cardiovascular diseases and helps decrease the risk of events such as stroke, myocardial infarction, and complications post-arterial revascularization. Therefore, this medication is used in the treatment of patients who have both hypertension and lipid abnormalities.
This drug is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased up to a maximum of 40 mg daily. The antihypertensive effect appears within 2 weeks after initiation of treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this drug alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). For patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is closely monitored. 2. Older adults No dosage adjustment is necessary when this drug is administered to older adults aged 65 years or older. Although no overall differences in efficacy and safety have been observed between older and younger patients, the possibility of a more sensitive response in some older adults cannot be excluded. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20 mg once daily. 4. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, which may be increased up to a maximum of 20 mg daily. Use of this drug is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 mg daily. 2. Older adults No dosage adjustment is necessary. 3. Patients with renal impairment No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.
Pediatric patients under 18 years of age: Safety and efficacy have not been established.
This drug may cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any ingredient of this medication, women who are pregnant or nursing, patients with severely impaired kidney or liver function, and those with specific muscle diseases should not take this medication. Extreme caution should be exercised in patients with very low blood pressure or unstable kidney function as using this drug may lead to lowered blood pressure and worsened kidney function. Symptoms such as muscle pain, muscle weakness, or myopathy may occur, so if these symptoms arise, patients should immediately inform healthcare personnel and may need to discontinue medication if necessary. This drug can affect liver function, so liver function tests should be conducted regularly before and during treatment, particularly in patients with a history of liver disease. Drug interactions may occur, so patients must inform healthcare personnel of all medications currently being taken. Elderly patients or those with impaired kidney function may experience an increased concentration of this drug in their bodies, necessitating dose adjustments and careful monitoring. In the case of overdose, a decrease in blood pressure or arrhythmias may occur, necessitating immediate medical attention. Since there is no specific antidote, treatment will be symptomatic. The safety and efficacy of this medication have not been thoroughly established for children under 18, so it is advisable not to use it in this age group. During treatment, patients should avoid alcohol, and be cautious when engaging in activities that could be dangerous, such as driving or operating machinery, as dizziness or drowsiness may occur.
Increased ALT, increased AST, elevated blood creatinine, decreased creatinine clearance, headache, dizziness, sensory reduction, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness including orthostatic dizziness, palpitations, hypertension, low back pain, increased blood creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reaction including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscular weakness, oculobulbar weakness
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius. This helps to maintain the drug's efficacy and safety.
Pink, round, film-coated tablets
30 tablets/PTP[((10 tablets/PTP)x3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Mothers Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.